TYMP
protein-codingthymidine phosphorylase, the group of Minor histocompatibility antigens
Gene summary
This gene encodes an angiogenic factor which promotes angiogenesis in vivo and stimulates the in vitro growth of a variety of endothelial cells. It has a highly restricted target cell specificity acting only on endothelial cells. Mutations in this gene have been associated with mitochondrial neurogastrointestinal encephalomyopathy. Multiple alternatively spliced transcript variants have been identified. [provided by RefSeq, Apr 2012]
- MNGIE
- ECGF1
MANE transcript
Inheritance
ClinVar variants
Top phenotype
gnomAD constraint
Max pathogenic AF
Genomic locus
External References & Databases
Transcript & Mutation Effects
hg38 • Region Span ~4.3 kbGenCC Phenotypes & Disease Associations
Curated gene-disease validity assertions and inheritance patterns
Inheritance Pattern: AR
Disease ID:MONDO:0011283
Submitter: PanelApp Australia
Inheritance Pattern: AR
Disease ID:MONDO:0044970
Submitter: ClinGen
The relationship between *TYMP* and primary mitochondrial disease was evaluated using the ClinGen Clinical Validity Framework as of October 2, 2023. The *TYMP* gene encodes thymidine phosphorylase (TP), which catalyzes the conversion of thymidine to thymine and 2-deoxy-D-ribose 1-phosphate. Thymidine-to-thymine conversation is important for nucleoside catabolism. The *TYMP* gene was first reported in relation to autosomal recessive mitochondrial neurogastrointestinal encephalopathy (MNGIE) in 1999 (PMID: 9924029). While various names have been given to the constellation of features seen in those with *TYMP*-related disease, pathogenic variants in this gene cause a primary mitochondrial disease. Therefore, the *TYMP* phenotype has been lumped into one disease entity according to the ClinGen Lumping and Splitting Framework. Evidence supporting this gene-disease relationship includes case-level data and experimental data. This curation included nine unique missense variants, three canonical splice variants, and two frameshift variants reported in 14 unrelated individuals described in two publications (PMIDs: 9924029, 15781193). Additional cases are available in the literature, but the maximum for genetic evidence has been reached. MNGIE is a multisystem disorder caused by TP deficiency that results in severe gastrointestinal dysmotility and skeletal muscle abnormalities due to mtDNA depletion and the accumulation of mtDNA deletions and duplications in various tissues over time. While intrafamilial phenotypic variability and patients with incomplete or atypical clinical manifestations have been described, MNGIE is the only phenotype that has been reported in association with variants in *TYMP*. Later-onset disease has been described for some variants with a less severe impact on TP function. The mechanism of disease is loss of function. This gene-disease relationship is also supported by a role in mitochondrial DNA maintenance shared with other genes associated with primary mitochondrial disease; rescue of TYMP mRNA and protein levels, TP activity, and nucleoside catabolism via delivery of an intact copy of the human gene in patient cells; and improved disease-related plasma metabolite levels and clinical measures of disease following enzyme replacement therapy in human patients (PMIDs: 12077348, 21451581, 30959750). Of note, mice with knockout of TP do not show a phenotype since, unlike humans, mice can use uridine phosphorylase (UP) to clear thymidine, compensating for the absence of TP. However, a mouse model with double knockout of TP and UP recapitulates some clinical and biochemical features of the disorder, which can be rescued by wildtype gene expression (PMID: 21451581). In summary, there is definitive evidence to support the relationship between *TYMP* and autosomal recessive primary mitochondrial disease. This relationship has been repeatedly demonstrated in both the research and clinical diagnostic settings and has been upheld over time. This classification was approved by the NICHD/NINDS U24 ClinGen Mitochondrial Disease Gene Curation Expert Panel on October 2, 2023 (SOP Version 9).
Inheritance Pattern: AR
Disease ID:MONDO:0011283
Submitter: Natera
Inheritance Pattern: AR
Disease ID:MONDO:0011283
Submitter: Labcorp Genetics (formerly Invitae)
Inheritance Pattern: AR
Disease ID:MONDO:0017575
Submitter: Orphanet
Clinical Genomic Database (CGD)
Manifestation: Biochemical; Gastrointestinal; Musculoskeletal; Neurologic
Intervention: Biochemical; Gastrointestinal
Rationale: Liver transplantation has been described as resulting in short-term survival, stabilization of disease symptoms, decrease in thymidine levels, and clinical improvements
Comments: Liver transplantation has been described as resulting in short-term survival, stabilization of disease symptoms, decrease in thymidine levels, and clinical improvements
ClinVar Associated Diseases & Phenotypes
Reported disease conditions connected to TYMP variants in ClinVar
ClinVar Variants & Pathogenicity by Type
Statistics based on transcript NM_001953.5. Only rare variants are included.
We include only reliable ClinVar variants with their consequences to MANE Select, MANE Plus Clinical transcripts, or transcripts with TSL equal to 1. Click a count to filter the variants table below.
Slight differences between displayed counts and ClinVar may occur due to a different transcript/consequence chosen by our variant effect predictor, or because we classify Benign/Likely benign as Likely benign and Pathogenic/Likely pathogenic as Likely pathogenic.
| Effect | PathogenicP | Likely pathogenicLP | VUS | Likely benignLB | BenignB | Sum |
|---|---|---|---|---|---|---|
| synonymous | 12 | 373 | 2 | 387 | ||
| missense | 21 | 37 | 250 | 20 | 2 | 330 |
| nonsense | 21 | 16 | 2 | 39 | ||
| start loss | 0 | |||||
| frameshift | 73 | 30 | 103 | |||
| splice donor/acceptor (+/-2bp) | 16 | 27 | 43 | |||
| Total | 131 | 110 | 264 | 393 | 4 | 902 |
Highest pathogenic variant AF is 0.00044118596
Transcript Catalog
Annotated transcript isoforms across RefSeq and Ensembl databases
| Transcript ID | Source | Protein ID | Coding Exons | MANE Status |
|---|---|---|---|---|
| RefSeq | NP_001944.1 | 9 | MANE Select | |
| Ensembl | ENSP00000252029.3 | 9 | MANE Select | |
| RefSeq | NP_001107227.1 | 9 | Standard | |
| RefSeq | NP_001107228.1 | 9 | Standard |
Gene Ontology (GO) Annotations & Pathways
Biological processes, molecular functions, cellular components and pathways
Pathways ConsensusPathDB
- Pyrimidine metabolism - Homo sapiens (human)
- Bladder cancer - Homo sapiens (human)
- Drug metabolism - other enzymes - Homo sapiens (human)
- Fluoropyrimidine Pathway, Pharmacokinetics
- Pyrimidine Metabolism
Biological Process
- mitochondrial genome maintenance
- angiogenesis
- pyrimidine nucleobase metabolic process
- pyrimidine nucleoside metabolic process
- chemotaxis
Molecular Function
- phosphorylase activity
- growth factor activity
- thymidine phosphorylase activity
- pyrimidine-nucleoside phosphorylase activity
- transferase activity, transferring pentosyl groups
Cellular Component
- cytosol
gnomAD Constraint
Source:
- Gene type
- protein_coding
- Transcript type
- protein_coding
- Transcript
- ENST00000395681
- Coding exons
- 9
- Length
- 4305
- Individuals with no LoFs
- 125706
- Homozygous LoFs
- 0
- Heterozygous LoFs
- 29
- Defined
- 125735
- p
- 0.000115
| Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible | |
|---|---|---|---|---|---|---|
| Missense | -0.0969 | 276 | 272 | 1.02 | 0.0000150 | 2987 |
| Missense (PolyPhen) | 94 | 104 | 0.90381 | 1171 | ||
| Synonymous | -0.793 | 139 | 128 | 1.09 | 0.00000760 | 1100 |
| Loss of Function | 1.82 | 9 | 17.1 | 0.525 | 8.71e-7 | 185 |
Population LoF Frequency
| Population | CAF | p-value | Status |
|---|---|---|---|
| African | 0.00014 | 0.00012 | rare |
| Latino/Admixed American | 0.00032 | 0.00032 | rare |
| Ashkenazi Jewish | 0 | 0.0 | absent |
| East Asian | 0.00011 | 0.00011 | rare |
| Finnish | 0 | 0.0 | absent |
| European (Non-Finnish) | 0.000098 | 0.000097 | rare |
| South Asian | 0.000033 | 0.000033 | rare |
| Other | 0.00034 | 0.00033 | rare |
dbNSFP Gene Annotations
Source:
- Function
- FUNCTION: May have a role in maintaining the integrity of the blood vessels. Has growth promoting activity on endothelial cells, angiogenic activity in vivo and chemotactic activity on endothelial cells in vitro. {ECO:0000269|PubMed:1590793}.;
- Disease
- DISEASE: Mitochondrial DNA depletion syndrome 1, MNGIE type (MTDPS1) [MIM:603041]: A multisystem disease associated with mitochondrial dysfunction. It is clinically characterized by onset between the second and fifth decades of life, ptosis, progressive external ophthalmoplegia, gastrointestinal dysmotility (often pseudoobstruction), diffuse leukoencephalopathy, cachexia, peripheral neuropathy, and myopathy. {ECO:0000269|PubMed:12177387, ECO:0000269|PubMed:9924029}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
Recessive Scores
- pRec
- 0.509
Essentials
- Essential (CRISPR)
- N
- Essential (CRISPR2)
- N
- Essential (gene trap)
- N
- Indispensability pred.
- E
- Indispensability score
- 0.555
Gene Damage Prediction
| All | Recessive | Dominant | |
|---|---|---|---|
| Mendelian | Medium | Medium | Medium |
| Primary Immunodeficiency | Medium | Medium | Medium |
| Cancer | Medium | Medium | Medium |